[go: up one dir, main page]

MX2016012530A - Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso. - Google Patents

Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.

Info

Publication number
MX2016012530A
MX2016012530A MX2016012530A MX2016012530A MX2016012530A MX 2016012530 A MX2016012530 A MX 2016012530A MX 2016012530 A MX2016012530 A MX 2016012530A MX 2016012530 A MX2016012530 A MX 2016012530A MX 2016012530 A MX2016012530 A MX 2016012530A
Authority
MX
Mexico
Prior art keywords
methods
influenza
hemagglutinin antibodies
virus hemagglutinin
virus
Prior art date
Application number
MX2016012530A
Other languages
English (en)
Inventor
Gerald R Nakamura
Henry Chiu
Mercedesz Balazs
Nancy Chiang
Zhonghua Lin
Swem Lee
Xu Min
Chai Ning
Park Hyunjoo
Original Assignee
Genentech Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Genentech Inc filed Critical Genentech Inc
Publication of MX2016012530A publication Critical patent/MX2016012530A/es

Links

Classifications

    • C07K16/108—
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39583—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials not provided for elsewhere, e.g. haptens, coenzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Virology (AREA)
  • Emergency Medicine (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Pulmonology (AREA)
  • Molecular Biology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención proporciona anticuerpos de hemaglutinina contra el virus de la influenza B, composiciones que comprenden anticuerpos de hemaglutinina contra el virus de la influenza B y sus métodos de uso.
MX2016012530A 2014-03-27 2015-03-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso. MX2016012530A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461971123P 2014-03-27 2014-03-27
PCT/US2015/022758 WO2015148806A1 (en) 2014-03-27 2015-03-26 Anti-influenza b virus hemagglutinin antibodies and methods of use

Publications (1)

Publication Number Publication Date
MX2016012530A true MX2016012530A (es) 2017-01-05

Family

ID=52829396

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016012530A MX2016012530A (es) 2014-03-27 2015-03-26 Anticuerpos de hemaglutinina contra el virus de la influenza b y metodos de uso.

Country Status (20)

Country Link
US (2) US9745365B2 (es)
EP (1) EP3122771A1 (es)
JP (1) JP2017512471A (es)
KR (1) KR20160135830A (es)
CN (1) CN106132987A (es)
AR (1) AR099855A1 (es)
AU (1) AU2015235983A1 (es)
BR (1) BR112016022113A2 (es)
CA (1) CA2942820A1 (es)
CL (2) CL2016002413A1 (es)
CR (1) CR20160502A (es)
EA (1) EA201691945A1 (es)
IL (1) IL247870A0 (es)
MA (1) MA39803A (es)
MX (1) MX2016012530A (es)
PE (1) PE20161376A1 (es)
PH (1) PH12016501873A1 (es)
SG (1) SG11201607945UA (es)
TW (1) TW201620932A (es)
WO (1) WO2015148806A1 (es)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP7181091B2 (ja) 2016-05-10 2022-11-30 ジェネンテック， インコーポレイテッド ポリペプチドの組み換え産生中にトリスルフィド結合を減少させる方法
CA3254669A1 (en) 2017-12-22 2025-04-25 Genentech, Inc. TARGETED NUCLEIC ACID INTEGRATION
BR112020014849A2 (pt) 2018-01-26 2020-12-08 Regeneron Pharmaceuticals, Inc. Anticorpo recombinante isolado ou seu fragmento de ligação ao antígeno, composição farmacêutica, molécula polinucleotídica isolada, vetor, célula, e, método para prevenir, tratar ou melhorar pelo menos um sintoma de infecção por influenza
WO2019191552A1 (en) 2018-03-29 2019-10-03 Genentech, Inc. Modulating lactogenic activity in mammalian cells
CN113631711B (zh) 2018-12-21 2025-03-04 豪夫迈·罗氏有限公司 核酸的靶向整合
RU2714246C1 (ru) * 2018-12-28 2020-02-13 Федеральное государственное бюджетное учреждение "Научно-исследовательский институт гриппа имени А.А. Смородинцева" Министерства здравоохранения Российской Федерации Моноклональные антитела, специфичные к различным штаммам вируса гриппа в
CN114761428A (zh) * 2019-10-28 2022-07-15 瑞泽恩制药公司 抗血凝素抗体及其使用方法
CN115348874A (zh) * 2020-01-24 2022-11-15 里珍纳龙药品有限公司 蛋白质-抗病毒化合物偶联物
US12098365B2 (en) 2020-03-26 2024-09-24 Genentech, Inc. Modified mammalian cells
MX2022015205A (es) 2020-06-24 2023-01-05 Genentech Inc Integracion dirigida de acidos nucleicos.
EP4172192A1 (en) 2020-06-24 2023-05-03 Genentech, Inc. Apoptosis resistant cell lines
TW202227625A (zh) 2020-08-28 2022-07-16 美商建南德克公司 宿主細胞蛋白質之ＣＲＩＳＰＲ／Ｃａｓ９多重剔除
CN114316032B (zh) * 2020-09-27 2022-12-27 东莞市朋志生物科技有限公司 抗乙型流感病毒的抗体、检测乙型流感病毒的试剂和试剂盒
EP4326855A1 (en) 2021-04-19 2024-02-28 Genentech, Inc. Modified mammalian cells
JP2024521107A (ja) 2021-05-21 2024-05-28 ジェネンテック， インコーポレイテッド 目的の組換え産物を産生するための修飾細胞
EP4619413A2 (en) 2022-11-14 2025-09-24 Janssen Vaccines & Prevention B.V. Influenza b virus vaccines and uses thereof
EP4619511A1 (en) 2022-11-15 2025-09-24 Genentech, Inc. Combined transposon-mediated integration and targeted integration of nucleic acids into host cells
WO2024151974A1 (en) 2023-01-12 2024-07-18 Genentech, Inc. Combinatorial vector cloning and transfection strategies for targeted integration of nucleic acids
US20250011420A1 (en) * 2023-07-03 2025-01-09 Medicovestor, Inc. Proteins that bind sp17 including fully-human anti-sp17 antibodies
US12319747B2 (en) 2023-07-03 2025-06-03 Medicovestor, Inc. Methods of using anti-SP17 immunotherapeutics
US12364777B2 (en) 2023-10-20 2025-07-22 Medicovestor, Inc. Homodimeric antibodies for use in treating cancers and methods of use
US12116410B1 (en) 2023-12-26 2024-10-15 Medicovestor, Inc. Methods of manufacturing dimeric antibodies

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2921928B1 (fr) 2007-10-08 2011-03-04 Sanofi Pasteur Anticorps monoclonaux specifiques de l'hemagglutinine du virus grippal
BE1018561A3 (fr) 2008-12-24 2011-03-01 Galactic Sa Procede de purification de l'acide lactique par cristallisation.
EP2380976A4 (en) 2008-12-25 2012-11-07 Univ Osaka HUMAN ANTIBODY AGAINST HUMAN FLUX VIRUS
WO2013007770A1 (en) 2011-07-14 2013-01-17 Crucell Holland B.V. Human binding molecules capable of neutralizing influenza a viruses of phylogenetic group 1 and phylogenetic group 2 and influenza b viruses
JP6170507B2 (ja) 2012-01-31 2017-07-26 国立大学法人大阪大学 Ｂ型インフルエンザウイルスに対する広範な保護を与えるヒトモノクローナル抗体及びその使用方法
CA2865594C (en) * 2012-03-08 2021-07-27 Crucell Holland B.V. Human binding molecules capable of binding to and neutralizing influenza b viruses and uses thereof

Also Published As

Publication number Publication date
KR20160135830A (ko) 2016-11-28
CN106132987A (zh) 2016-11-16
PE20161376A1 (es) 2016-12-26
US9745365B2 (en) 2017-08-29
JP2017512471A (ja) 2017-05-25
WO2015148806A1 (en) 2015-10-01
AR099855A1 (es) 2016-08-24
TW201620932A (zh) 2016-06-16
SG11201607945UA (en) 2016-10-28
US20150274812A1 (en) 2015-10-01
IL247870A0 (en) 2016-11-30
AU2015235983A1 (en) 2016-10-06
CA2942820A1 (en) 2015-10-01
MA39803A (fr) 2017-02-01
EP3122771A1 (en) 2017-02-01
BR112016022113A2 (pt) 2017-10-31
CR20160502A (es) 2017-02-03
EA201691945A1 (ru) 2017-02-28
PH12016501873A1 (en) 2017-01-09
CL2016002413A1 (es) 2017-06-23
CL2018002874A1 (es) 2018-12-14
US20170320937A1 (en) 2017-11-09

Similar Documents

Publication Publication Date Title
CL2018002874A1 (es) Anticuerpos de hemaglutinina contra el virus de la influenza b y métodos de uso (divisional de solicitud n° 2413-2016).
CY1124521T1 (el) Σκευασματα αντισωματος anti-cd19
MX2017005920A (es) Anticuerpos anti-tim3 y metodos de uso.
MX2017007049A (es) Anticuerpos anti-cd79b y métodos de uso.
EP3538146A4 (en) INFLUENZA VACCINE
BR112016022658A2 (pt) anticorpos anti-ox40 e métodos de uso
MX2017000395A (es) Vacunas contra virus influenza y usos de las mismas.
MX2016014247A (es) Conjugados de anticuerpo-farmaco anti-proteina tirosina quinasa 7 (anti-ptk7).
BR112017008666A2 (pt) anticorpos anti-fgfr2/3 e métodos de uso dos mesmos
MX2015016755A (es) Reagrupamiento del virus de influenza.
MX2016010433A (es) Anticuerpos anti-jagged1 y metodos de uso.
MX2017001279A (es) Usos y composiciones de la flagelina.
EA201692541A1 (ru) Вакцины против вируса гриппа и их применения
BR112017005266A2 (pt) inibidores de mk2 e uso dos mesmos
CR20150247A (es) Anticuerpos de antihemaglutinina y métodos de uso
BR112017000456A2 (pt) composições antivirais tópicas e métodos de uso das mesmas
MX2016016301A (es) Procesos de siembra en serie y usos de los mismos.
CR20160468A (es) Conservación de productos perecederos a base de biopolímeros
MX389001B (es) Moduladores de interacción de sestrina-gator2 y sus usos.
BR112019010131A2 (pt) entrega transdérmica de agentes grandes
CL2019000049A1 (es) Procesos para la preparación de oxipicolinamidas 4 - alkoxi - (acil o aquil).
EP3528827A4 (en) Influenza hemagglutinin protein vaccines
BR112017002090A2 (pt) formulação de fator viii
UY36217A (es) Compuestos piridona sustituídos, composiciones farmacéuticas y métodos de uso.
MX2016016233A (es) Anticuerpos anti-lgr5 y sus usos.